These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations. Perna F; Parekh S; Diorio C; Smith M; Subklewe M; Mehta R; Locke FL; Shah NN Blood Adv; 2024 Aug; 8(16):4348-4358. PubMed ID: 38861351 [TBL] [Abstract][Full Text] [Related]
25. [Practical aspects of the application of CAR T cells and management of their toxicities]. Bücklein V; Blumenberg V; Subklewe M Dtsch Med Wochenschr; 2021 Sep; 146(17):1129-1137. PubMed ID: 34448189 [TBL] [Abstract][Full Text] [Related]
26. Mechanisms and strategies for safe chimeric antigen receptor T-cell activity control. Stock S; Klüver AK; Fertig L; Menkhoff VD; Subklewe M; Endres S; Kobold S Int J Cancer; 2023 Nov; 153(10):1706-1725. PubMed ID: 37350095 [TBL] [Abstract][Full Text] [Related]
27. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. Freyer CW; Porter DL J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558 [TBL] [Abstract][Full Text] [Related]
28. Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis. Willyanto SE; Alimsjah YA; Tanjaya K; Tuekprakhon A; Pawestri AR Ann Med; 2024 Dec; 56(1):2349796. PubMed ID: 38738799 [TBL] [Abstract][Full Text] [Related]
29. Early and Late Toxicities of Chimeric Antigen Receptor T-Cells. Epperly R; Giordani VM; Mikkilineni L; Shah NN Hematol Oncol Clin North Am; 2023 Dec; 37(6):1169-1188. PubMed ID: 37349152 [TBL] [Abstract][Full Text] [Related]
30. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. Rafei H; Daher M; Rezvani K Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984 [TBL] [Abstract][Full Text] [Related]
31. INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities. McNerney KO; Hsieh EM; Shalabi H; Epperly R; Wolters PL; Hill JA; Gardner R; Talleur AC; Shah NN; Rossoff J Transplant Cell Ther; 2024 Jan; 30(1):38-55. PubMed ID: 37821079 [TBL] [Abstract][Full Text] [Related]
33. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. Gutierrez C; Brown ART; Herr MM; Kadri SS; Hill B; Rajendram P; Duggal A; Turtle CJ; Patel K; Lin Y; May HP; Gallo de Moraes A; Maus MV; Frigault MJ; Brudno JN; Athale J; Shah NN; Kochenderfer JN; Dharshan A; Beitinjaneh A; Arias AS; McEvoy C; Mead E; Stephens RS; Nates JL; Neelapu SS; Pastores SM J Crit Care; 2020 Aug; 58():58-64. PubMed ID: 32361219 [TBL] [Abstract][Full Text] [Related]
34. Monitoring and safety of CAR-T therapy in clinical practice. Serra López-Matencio JM; Gómez Garcia de Soria V; Gómez M; Alañón-Plaza E; Muñoz-Calleja C; Castañeda S Expert Opin Drug Saf; 2022 Mar; 21(3):363-371. PubMed ID: 34519234 [TBL] [Abstract][Full Text] [Related]
35. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. Hay KA Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609 [TBL] [Abstract][Full Text] [Related]
37. Neurological Complications of CAR T Cell Therapy. Landry K; Thomas AA Curr Oncol Rep; 2020 Jul; 22(8):83. PubMed ID: 32607727 [TBL] [Abstract][Full Text] [Related]
38. Recognizing, defining, and managing CAR-T hematologic toxicities. Rejeski K; Subklewe M; Locke FL Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):198-208. PubMed ID: 38066881 [TBL] [Abstract][Full Text] [Related]
39. Potentially fatal complications of new systemic anticancer therapies: pearls and pitfalls in their initial management. Kovac MB; Seruga B Radiol Oncol; 2024 Jun; 58(2):170-178. PubMed ID: 38613842 [TBL] [Abstract][Full Text] [Related]
40. Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy. Hoogland AI; Barata A; Logue J; Kommalapati A; Hyland KA; Nelson AM; Eisel SL; Small BJ; James BW; Christy SM; Bulls HW; Booth-Jones M; Jayani RV; Jain MD; Mokhtari S; Chavez JC; Lazaryan A; Shah BD; Locke FL; Jim HSL Transplant Cell Ther; 2022 Jun; 28(6):305.e1-305.e9. PubMed ID: 35378330 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]